There is increasing evidence that elevated levels of the beta-adrenergic receptor kinase1 (betaARK1) contribute to impaired catecholamine responsiveness observed in heart failure. Using a gene targeted mouse model of heart failure (MLP-/-), we have recently shown that reversal of betaAR desensitization achieved through betaARK1 inhibition, could lead to a marked improvement in cardiac function. The overall hypothesis of this proposal is that increased beta1AR phosphorylation, as a consequence of elevated betaARK1 levels, not only contributes to, but is a primary cause of heart failure. The following specific aims are proposed 1) To determine the role beta1AR phosphorylation and betaARK1 play in the development of the failing heart and whether high levels of circulating catecholamines are required for the pathogenesis of heart failure; MLP(-/-) mice will be crossed with betaARK1 heterozygous knockout mice and dopamine-beta-hydroxylase knockout mice. 2) To determine whether the salutary effects of betaARK1 inhibition represent a ubiquitous pathologic mechanism; another model of severe cardiac dysfunction and premature death achieved through cardiac targeted overexpression of calsequestrin will be crossed into transgenic mice overexpressing the betaARK inhibitor 3) To determine whether betaARK1 phosphorylation of the beta1AR is a mechanism for the pathogenesis of the failing heart, the carboxyl terminal phosphorylation sites for betaARK1 will be mutated by site directed mutagenesis and tested both in vitro and in vivo for the capacity to prevent phosphorylation and desensitization of beta1AR's 4) To determine whether beta1AR desensitization by betaARK1 is a primary pathologic mechanism for the development of heart failure; beta1AR phosphorylation mutant mice will be crossed into the MLP (-/-) heart failure mouse. Using an integrative approach with novel gene targeting strategies and in-depth physiological analysis of gene targeted mice, we will directly test the hypothesis that desensitization of beta1AR's, mediated through heightened betaARK1 levels, play a causative role in the pathogenesis of the failing heart. The collaborations with the other R01's should provide a unique opportunity to understand the relationships between betaAR signaling, E-C coupling and myocyte cell survival.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL061558-03
Application #
6139307
Study Section
Special Emphasis Panel (ZHL1-CSR-F (S1))
Project Start
1999-01-11
Project End
2003-12-31
Budget Start
2000-01-01
Budget End
2000-12-31
Support Year
3
Fiscal Year
2000
Total Cost
$317,861
Indirect Cost
Name
Duke University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
071723621
City
Durham
State
NC
Country
United States
Zip Code
27705
Yoo, ByungSu; Lemaire, Anthony; Mangmool, Supachoke et al. (2009) Beta1-adrenergic receptors stimulate cardiac contractility and CaMKII activation in vivo and enhance cardiac dysfunction following myocardial infarction. Am J Physiol Heart Circ Physiol 297:H1377-86
Volovyk, Zoya M; Wolf, Matthew J; Prasad, Sathyamangla V Naga et al. (2006) Agonist-stimulated beta-adrenergic receptor internalization requires dynamic cytoskeletal actin turnover. J Biol Chem 281:9773-80
Perrino, Cinzia; Naga Prasad, Sathyamangla V; Patel, Mrinali et al. (2005) Targeted inhibition of beta-adrenergic receptor kinase-1-associated phosphoinositide-3 kinase activity preserves beta-adrenergic receptor signaling and prolongs survival in heart failure induced by calsequestrin overexpression. J Am Coll Cardiol 45:1862-70
Perrino, Cinzia; Naga Prasad, Sathyamangla V; Schroder, Jacob N et al. (2005) Restoration of beta-adrenergic receptor signaling and contractile function in heart failure by disruption of the betaARK1/phosphoinositide 3-kinase complex. Circulation 111:2579-87
Seubert, John; Yang, Baichun; Bradbury, J Alyce et al. (2004) Enhanced postischemic functional recovery in CYP2J2 transgenic hearts involves mitochondrial ATP-sensitive K+ channels and p42/p44 MAPK pathway. Circ Res 95:506-14
Colomer, Josep M; Mao, Lan; Rockman, Howard A et al. (2003) Pressure overload selectively up-regulates Ca2+/calmodulin-dependent protein kinase II in vivo. Mol Endocrinol 17:183-92
Esposito, Giovanni; Rapacciuolo, Antonio; Naga Prasad, Sathyamangla V et al. (2002) Genetic alterations that inhibit in vivo pressure-overload hypertrophy prevent cardiac dysfunction despite increased wall stress. Circulation 105:85-92
Naga Prasad, Sathyamangla V; Laporte, Stephane A; Chamberlain, Dean et al. (2002) Phosphoinositide 3-kinase regulates beta2-adrenergic receptor endocytosis by AP-2 recruitment to the receptor/beta-arrestin complex. J Cell Biol 158:563-75
Rapacciuolo, A; Esposito, G; Caron, K et al. (2001) Important role of endogenous norepinephrine and epinephrine in the development of in vivo pressure-overload cardiac hypertrophy. J Am Coll Cardiol 38:876-82
Harding, V B; Jones, L R; Lefkowitz, R J et al. (2001) Cardiac beta ARK1 inhibition prolongs survival and augments beta blocker therapy in a mouse model of severe heart failure. Proc Natl Acad Sci U S A 98:5809-14

Showing the most recent 10 out of 13 publications